Table 1.
Expression pattern of MMR protein and clinicopathological characteristics of CRC
| MSS (38) |
MSI (77) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | C | D | E | F | G | H | I | J | P | |||
| n | 38 | 1 | 29 | 22 | 1 | 1 | 4 | 7 | 9 | 3 | |||
| Gender | M | n | 25 | 0 | 18 | 14 | 0 | 1 | 2 | 5 | 5 | 2 | 0.84 |
| % | 66 | 0 | 62 | 64 | 0 | 100 | 50 | 71 | 56 | 67 | |||
| F | n | 13 | 1 | 11 | 8 | 1 | 0 | 2 | 2 | 4 | 1 | ||
| % | 34 | 100 | 38 | 36 | 100 | .0 | 50 | 29 | 44 | 33 | |||
| Age | < 50 | n | 17 | 1 | 13 | 13 | 1 | 1 | 2 | 2 | 2 | 1 | 0.51 |
| % | 45 | 100 | 45 | 59 | 100 | 100 | 50 | 29 | 22 | 33 | |||
| < 50 | n | 21 | 0 | 16 | 9 | 0 | 0 | 2 | 5 | 7 | 2 | ||
| % | 55 | 0 | 55 | 41 | 0 | 0 | 50 | 71 | 78 | 67 | |||
| R | n | 16 | 1 | 22 | 18 | 1 | 0 | 3 | 3 | 8 | 1 | 0.014* | |
| % | 42 | 100 | 76 | 82 | 100 | 0 | 75 | 43 | 89 | 33 | |||
| L | L | n | 22 | 0 | 7 | 4 | 0 | 1 | 1 | 4 | 1 | 2 | |
| % | 57.9 | 0 | 24 | 18 | 0 | 100 | 25 | 57.1 | 11.1 | 66.7 | |||
| LVE | A | n | 30 | 1 | 19 | 10 | 1 | 0 | 1 | 4 | 9 | 2 | 0.035* |
| % | 79 | 100 | 66 | 46 | 100 | 0 | 25 | 57 | 100 | 67 | |||
| P | n | 8 | 0 | 10 | 12 | 0 | 1 | 3 | 3 | 0 | 1 | ||
| % | 21 | 0 | 34 | 54 | 0 | 100 | 75 | 43 | 0 | 33 | |||
| PNI | A | n | 34 | 1 | 29 | 17 | 1 | 0 | 4 | 7 | 9 | 3 | 0.012* |
| % | 89.5 | 100 | 100 | 77 | 100 | 0 | 100 | 100 | 100 | 100 | |||
| P | n | 4 | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | ||
| % | 10.5 | 0 | 0 | 23 | 0 | 100 | 0 | 0 | 0 | 0 | |||
| G | G2 | n | 30 | 0 | 20 | 9 | 1 | 0 | 4 | 5 | 7 | 3 | 0.033* |
| % | 79 | 0 | 69 | 41 | 100 | 0 | 100 | 71 | 78 | 100 | |||
| G3 | n | 8 | 1 | 9 | 13 | 0 | 1 | 0 | 2 | 2 | 0 | ||
| % | 21 | 100 | 31 | 59 | 0 | 100 | 0 | 29 | 22 | 0 | |||
| T | T2 | n | 6 | 0 | 7 | 3 | 1 | 0 | 0 | 3 | 0 | 0 | 0.013* |
| % | 16 | 0 | 24 | 14 | 100 | 0 | 0 | 43 | 0 | 0 | |||
| T3 | n | 31 | 1 | 20 | 17 | 0 | 0 | 4 | 4 | 9 | 3 | ||
| % | 82 | 100 | 69 | 77 | 0 | 0 | 100 | 57 | 100 | 100 | |||
| T4 | n | 1 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | ||
| % | 3 | 0 | 7 | 9 | 0 | 100 | 0 | 0 | 0 | 0 | |||
| N | N0 | n | 20 | 0 | 23 | 11 | 1 | 0 | 1 | 5 | 9 | 2 | 0.000* |
| % | 53 | 0 | 79 | 50 | 100 | 0 | 25 | 71 | 100 | 67 | |||
| N1 | n | 5 | 1 | 4 | 10 | 0 | 0 | 3 | 2 | 0 | 1 | ||
| % | 13 | 100 | 14 | 45 | 0 | 0 | 75 | 29 | 0 | 33 | |||
| N2 | n | 13 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | ||
| % | 34 | 0 | 7 | 4 | 0 | 100 | 0 | 0 | 0 | 0 | |||
| V | NOS | n | 31 | 1 | 21 | 10 | 1 | 0 | 4 | 5 | 7 | 3 | 0.3 |
| % | 81 | 100 | 72 | 45 | 100 | 0 | 100 | 72 | 78 | 100 | |||
| MUC | n | 6 | 0 | 8 | 10 | 0 | 1 | 0 | 1 | 2 | 0 | ||
| % | 16 | 0 | 28 | 46 | 0 | 100 | 0 | 14 | 22 | 0 | |||
| Sign. | n | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | ||
| % | 3 | 0 | 0 | 9 | 0 | 0 | 0 | 14 | 0 | 0 | |||
G: Gender; L: Laterality; LVE: Lymphovascular Emboli; PNI: perineural Invasion; T: T stage; N: Nodal stage; V: Histopathologic variant; NOS: Non otherwise specified; and MUC: Mucinous; sign: signet ring; A: no loss of expression of any marker; B: loss of expression of all markers; C: loss of expression of both MLH, and PMS2; D: loss of expression of both MSH2, and MSH6; E: loss of expression of both of MSH6, and PMS2; F: loss of expression of both of MLH, and MSH2; G: isolated loss of expression of MLH; H: isolated loss of expression of MSH2; I: isolated loss of expression of MSH6; J: isolated loss of expression of PMS2.